[CH2:1]([NH:5][C:6]1[CH:7]=[CH:8][C:9]2[N:10]([C:12](B(O)O)=[CH:13][N:14]=2)[N:11]=1)[CH2:2][CH2:3][CH3:4].Br[C:19]1[N:20]=[CH:21][NH:22][CH:23]=1.P([O-])([O-])([O-])=O.[K+].[K+].[K+].COCCOC>C1C=CC(P(C2C=CC=CC=2)[C-]2C=CC=C2)=CC=1.C1C=CC(P(C2C=CC=CC=2)[C-]2C=CC=C2)=CC=1.Cl[Pd]Cl.[Fe+2].O>[CH2:1]([NH:5][C:6]1[CH:7]=[CH:8][C:9]2[N:10]([C:12]([C:19]3[N:20]=[CH:21][NH:22][CH:23]=3)=[CH:13][N:14]=2)[N:11]=1)[CH2:2][CH2:3][CH3:4]A mixture of (6-(butylamino)imidazo[1,2-b]pyridazin-3-yl)boronic acid (120 mg, 0.5 mmol), 4-bromo-1H-imidazole (75 mg, 0.5 mmol), dichloro[1,1′-bis(diphenylphosphino)ferrocene]palladium (II) dichloromethane adduct (40 mg, 0.050 mmol), potassium phosphate (210 mg, 1.0 mmol), DME (1.5 mL) and H2O (0.5 mL) was heated in a sealed conical vessel at 140° C. for 600 s by microwave irradiation. The organic layer was separated and the aqueous layer was extracted with ethyl acetate (2 mL). The combined organic layers were concentrated under reduced pressure to afford an oil that was purified by reverse phase HPLC to afford butyl-[3-(1H-imidazol-4-yl)-imidazo[1,2-b]pyridazin-6-yl]-amine (95 mg, 72%) as a white solid: 1H NMR (400 MHz, METHANOL-d4) δ ppm 7.99 (br. s., 1H), 7.82 (d, J=1.0 Hz, 2H), 7.60 (d, J=9.6 Hz, 1H), 6.68 (d, J=9.6 Hz, 1H), 3.44 (t, J=7.1 Hz, 2H), 1.69-1.82 (m, 2H), 1.46-1.60 (m, 2H), 1.03 (t, J=7.3 Hz, 3H); LCMS (ESI) m/e 257.2 [(M+H)+, calcd for C13H17N6 257.1].
読み込み中…
